Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, China.
Front Immunol. 2024 Aug 13;15:1407403. doi: 10.3389/fimmu.2024.1407403. eCollection 2024.
T cell immunoglobulin and mucin domain-3 (TIM-3), a crucial immune checkpoint following PD1 and CTLA4, is widely found in several immune cells. Nonetheless, its performance in recent clinical trials appears disappointing. Ovarian cancer (OC), a malignant tumor with a high mortality rate in gynecology, faces significant hurdles in immunotherapy. The broad presence of TIM-3 offers a new opportunity for immunotherapy in OC. This study reviews the role of TIM-3 in OC and assesses its potential as a target for immunotherapy. The regulatory effects of TIM-3 on the immune microenvironment in OC are discussed, with a focus on preclinical studies that demonstrate TIM-3's modulation of various immune cells in OC. Additionally, the potential therapeutic advantages and challenges of targeting TIM-3 in OC are examined.
T 细胞免疫球蛋白和黏蛋白结构域 3（TIM-3）是继 PD1 和 CTLA4 之后的一个关键免疫检查点，广泛存在于几种免疫细胞中。然而，其在最近的临床试验中的表现令人失望。卵巢癌（OC）是妇科中死亡率较高的恶性肿瘤，在免疫治疗方面面临重大障碍。TIM-3 的广泛存在为 OC 的免疫治疗提供了新的机会。本研究综述了 TIM-3 在 OC 中的作用，并评估了其作为免疫治疗靶点的潜力。讨论了 TIM-3 对 OC 免疫微环境的调节作用，重点介绍了临床前研究，这些研究表明 TIM-3 可调节 OC 中的各种免疫细胞。此外，还研究了靶向 TIM-3 在 OC 中的潜在治疗优势和挑战。
